Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Colorectal Cancer: Likelihood of Approval
Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Colorectal Cancer. According to...
Adebrelimab by Jiangsu Hengrui Medicine for Cervical Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Cervical Cancer. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Cervical Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Cervical Cancer. According to GlobalData,...
Fuzuloparib by Jiangsu Hengrui Medicine for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Fuzuloparib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction....
Adebrelimab by Jiangsu Hengrui Medicine for Advanced Malignancy: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Advanced Malignancy. According to GlobalData,...
Camrelizumab by Jiangsu Hengrui Medicine for Metastatic Melanoma: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Metastatic Melanoma. According to GlobalData,...
Ivarmacitinib sulfate by Jiangsu Hengrui Medicine for Graft Versus Host Disease (GVHD): Likelihood of Approval
Ivarmacitinib sulfate is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Graft Versus Host Disease...
Famitinib by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...
Camrelizumab by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...
Camrelizumab by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...
SHRA-1904 by Jiangsu Hengrui Medicine for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...
SHRA-1904 by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to GlobalData,...
SHR-1702 by Jiangsu Hengrui Medicine for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Refractory Acute Myeloid Leukemia. According...
Dexmedetomidine hydrochloride 1 by Jiangsu Hengrui Medicine for Pain: Likelihood of Approval
Dexmedetomidine hydrochloride 1 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Pain. According to...
SHRA-1904 by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
SHRA-1904 by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval
SHRA-1904 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Solid Tumor. According to GlobalData,...
SHR-1501 by Jiangsu Hengrui Medicine for Advanced Malignancy: Likelihood of Approval
SHR-1501 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Advanced Malignancy. According to GlobalData,...
SHR-1702 by Jiangsu Hengrui Medicine for Myelodysplastic Syndrome: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData,...
SHR-1702 by Jiangsu Hengrui Medicine for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...
Rafutrombopag by Jiangsu Hengrui Medicine for Thrombocytopenia: Likelihood of Approval
Rafutrombopag is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Thrombocytopenia. According to GlobalData, Phase...